IE
ERNA icon

Israel Englander’s Eterna Therapeutics ERNA Stock Holding History

Israel Englander’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-120
Closed -$13.2K – 5997
2024
Q4 		$13.2K Buy
+120
New +$32.5K ﹤0.01% 5760
2022
Q4 		– Sell
-112
Closed -$207K – 6678
2022
Q3 		$207K Buy
112
+68
+155% +$234K ﹤0.01% 5639
2022
Q2 		$170K Buy
+44
New +$316K ﹤0.01% 5712
2022
Q1 		– Sell
-3
Closed -$85K – 7043
2021
Q4 		$85K Hold
3
– – ﹤0.01% 6315
2021
Q3 		$187K Sell
3
-2
-40% -$173K ﹤0.01% 6150
2021
Q2 		$718K Buy
+5
New +$720K ﹤0.01% 4968

Other funds holding ERNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $77.5B AUM 27.94% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
SCA
Sippican Capital Advisors Boston, Massachusetts $164M AUM 35.17% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Israel Englander's ERNA Position: Q1 2025 in Review

Israel Englander sold out of Eterna Therapeutics (ERNA) in Q1 2025, closing a stake of 120 shares — an estimated $13.2K sold.

Israel Englander first reported a position in ERNA in Q2 2021 and held it in 6 quarters. The position peaked at $718K in Q2 2021. 20 funds tracked by Wall St. Rank hold ERNA as of Q1 2025.

  • Israel Englander reported no remaining Eterna Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 120 Eterna Therapeutics shares in Q1 2025, an estimated $13.2K.
  • Israel Englander first reported a position in Eterna Therapeutics in Q2 2021 and held it in 6 quarters.
  • Israel Englander's Eterna Therapeutics position peaked at $718K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.